Back to Search
Start Over
Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition.
- Source :
-
BMC cancer [BMC Cancer] 2024 Jun 03; Vol. 24 (1), pp. 676. Date of Electronic Publication: 2024 Jun 03. - Publication Year :
- 2024
-
Abstract
- Background: Circulating total insulin-like growth factor-I (IGF-I) is an established risk factor for prostate cancer. However, only a small proportion of circulating IGF-I is free or readily dissociable from IGF-binding proteins (its bioavailable form), and few studies have investigated the association of circulating free IGF-I with prostate cancer risk.<br />Methods: We analyzed data from 767 prostate cancer cases and 767 matched controls nested within the European Prospective Investigation into Cancer and Nutrition cohort, with an average of 14-years (interquartile range = 2.9) follow-up. Matching variables were study center, length of follow-up, age, and time of day and fasting duration at blood collection. Circulating free IGF-I concentration was measured in serum samples collected at recruitment visit (mean age 55 years old; standard deviation = 7.1) using an enzyme-linked immunosorbent assay (ELISA). Conditional logistic regressions were performed to examine the associations of free IGF-I with risk of prostate cancer overall and subdivided by time to diagnosis (≤ 14 and > 14 years), and tumor characteristics.<br />Results: Circulating free IGF-I concentrations (in fourths and as a continuous variable) were not associated with prostate cancer risk overall (odds ratio [OR] = 1.00 per 0.1 nmol/L increment, 95% CI: 0.99, 1.02) or by time to diagnosis, or with prostate cancer subtypes, including tumor stage and histological grade.<br />Conclusions: Estimated circulating free IGF-I was not associated with prostate cancer risk. Further research may consider other assay methods that estimate bioavailable IGF-I to provide more insight into the well-substantiated association between circulating total IGF-I and subsequent prostate cancer risk.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Male
Middle Aged
Case-Control Studies
Prospective Studies
Europe epidemiology
Aged
Risk Factors
Biomarkers, Tumor blood
Insulin-Like Peptides
Prostatic Neoplasms blood
Prostatic Neoplasms epidemiology
Prostatic Neoplasms pathology
Insulin-Like Growth Factor I metabolism
Insulin-Like Growth Factor I analysis
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2407
- Volume :
- 24
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC cancer
- Publication Type :
- Academic Journal
- Accession number :
- 38831273
- Full Text :
- https://doi.org/10.1186/s12885-023-11425-w